FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008208071> ?p ?o ?g. }

• W2008208071 endingPage "280" @default.
• W2008208071 startingPage "274" @default.
• W2008208071 abstract "Purpose: The efficacy of currently available topical hemostatic agents requires the formation of fibrin generated from circulating blood. Fibrin sealant, which is prepared from high concentrations of thrombin and fibrinogen, has been used in liquid form to promote hemostasis during vascular surgery. In a blinded, randomized, placebo-controlled fashion, we evaluated a dry dressing of purified, viral-inactivated human fibrinogen and human thrombin in a large animal model of arterial injury.Methods: Dressings were prepared by application of a layer of lyophilized human fibrin sealant or immunoglobulin G (IgG, control) to a silicone backing material. Six anesthetized female Yorkshire pigs (16 to 27 kg) received bilateral, 4 mm longitudinal femoral arteriotomies after surgical exposure of the arteries. The arteriotomies were not closed. In each animal a fibrin sealant dressing was applied to one artery and a control dressing to the other. Each dressing was secured on the arteriotomy by a mechanical device. After application of the dressings, blood flow was restored to each limb for 1 hour. The compressive device was released for 5 seconds at intervals of 15 minutes to assess hemostasis. Blood flow was measured distal to each arteriotomy with a dual-channel flowmeter to adjust equal bilateral compression.Results: Blood loss (mean ± SEM) was significantly less from the arteriotomy treated with the fibrin-based dressing compared with the control dressing (4.9 ± 4.0 ml versus 82.3 ± 11.1 ml; p = 0.0005). Complete hemostasis was achieved at the first 15-minute interval in five of six arteriotomies treated with fibrin sealant and in none of the six control arteriotomies during 1 hour of assessment ( p = 0.03). Blood flow through each femoral artery at baseline was the same in both treatment and control arteries (fibrin sealant, 114.2 ± 17.4 ml/min; control, 106.7 ±16.5 ml/min; p = 0.24) and was not significantly different throughout the experiment.Conclusions: Fibrin-based dressings provide effective hemostasis in a large animal model of arterial injury. Further development of these dressings will address optimal formulation and configuration for clinical use. Our results suggest that fibrin-based dressings will be effective in promotion of hemostasis in arterial bleeding, without compromising blood flow. (J Vasc Surg 1997 26:274-80.)" @default.
• W2008208071 created "2016-06-24" @default.
• W2008208071 creator A5003574797 @default.
• W2008208071 creator A5012084725 @default.
• W2008208071 creator A5020121535 @default.
• W2008208071 creator A5024216593 @default.
• W2008208071 creator A5026349065 @default.
• W2008208071 creator A5030868726 @default.
• W2008208071 creator A5038946058 @default.
• W2008208071 creator A5056837102 @default.
• W2008208071 date "1997-08-01" @default.
• W2008208071 modified "2023-09-25" @default.
• W2008208071 title "Hemostatic efficacy of a fibrin sealant–based topical agent in a femoral artery injury model: A randomized, blinded, placebo-controlled study" @default.
• W2008208071 cites W1972866336 @default.
• W2008208071 cites W1985030818 @default.
• W2008208071 cites W2002236404 @default.
• W2008208071 cites W2003252279 @default.
• W2008208071 cites W2009886507 @default.
• W2008208071 cites W2013776202 @default.
• W2008208071 cites W2014744268 @default.
• W2008208071 cites W2023396624 @default.
• W2008208071 cites W2034671085 @default.
• W2008208071 cites W2040423506 @default.
• W2008208071 cites W2041535925 @default.
• W2008208071 cites W2057492828 @default.
• W2008208071 cites W2077205820 @default.
• W2008208071 cites W2081645706 @default.
• W2008208071 cites W2082172508 @default.
• W2008208071 cites W2088294135 @default.
• W2008208071 cites W2089344564 @default.
• W2008208071 cites W2104605781 @default.
• W2008208071 cites W2406303201 @default.
• W2008208071 cites W2409946829 @default.
• W2008208071 cites W2416434098 @default.
• W2008208071 cites W4256455444 @default.
• W2008208071 doi "https://doi.org/10.1016/s0741-5214(97)70189-7" @default.
• W2008208071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9279315" @default.
• W2008208071 hasPublicationYear "1997" @default.
• W2008208071 type Work @default.
• W2008208071 sameAs 2008208071 @default.
• W2008208071 citedByCount "66" @default.
• W2008208071 countsByYear W20082080712012 @default.
• W2008208071 countsByYear W20082080712014 @default.
• W2008208071 countsByYear W20082080712015 @default.
• W2008208071 countsByYear W20082080712017 @default.
• W2008208071 countsByYear W20082080712020 @default.
• W2008208071 crossrefType "journal-article" @default.
• W2008208071 hasAuthorship W2008208071A5003574797 @default.
• W2008208071 hasAuthorship W2008208071A5012084725 @default.
• W2008208071 hasAuthorship W2008208071A5020121535 @default.
• W2008208071 hasAuthorship W2008208071A5024216593 @default.
• W2008208071 hasAuthorship W2008208071A5026349065 @default.
• W2008208071 hasAuthorship W2008208071A5030868726 @default.
• W2008208071 hasAuthorship W2008208071A5038946058 @default.
• W2008208071 hasAuthorship W2008208071A5056837102 @default.
• W2008208071 hasBestOaLocation W20082080711 @default.
• W2008208071 hasConcept C126322002 @default.
• W2008208071 hasConcept C141071460 @default.
• W2008208071 hasConcept C178790620 @default.
• W2008208071 hasConcept C185592680 @default.
• W2008208071 hasConcept C203014093 @default.
• W2008208071 hasConcept C2775883587 @default.
• W2008208071 hasConcept C2776820930 @default.
• W2008208071 hasConcept C2777292125 @default.
• W2008208071 hasConcept C2778589496 @default.
• W2008208071 hasConcept C2779036427 @default.
• W2008208071 hasConcept C2779450455 @default.
• W2008208071 hasConcept C2779723990 @default.
• W2008208071 hasConcept C2910835652 @default.
• W2008208071 hasConcept C2910882873 @default.
• W2008208071 hasConcept C42219234 @default.
• W2008208071 hasConcept C54173615 @default.
• W2008208071 hasConcept C71924100 @default.
• W2008208071 hasConcept C89560881 @default.
• W2008208071 hasConceptScore W2008208071C126322002 @default.
• W2008208071 hasConceptScore W2008208071C141071460 @default.
• W2008208071 hasConceptScore W2008208071C178790620 @default.
• W2008208071 hasConceptScore W2008208071C185592680 @default.
• W2008208071 hasConceptScore W2008208071C203014093 @default.
• W2008208071 hasConceptScore W2008208071C2775883587 @default.
• W2008208071 hasConceptScore W2008208071C2776820930 @default.
• W2008208071 hasConceptScore W2008208071C2777292125 @default.
• W2008208071 hasConceptScore W2008208071C2778589496 @default.
• W2008208071 hasConceptScore W2008208071C2779036427 @default.
• W2008208071 hasConceptScore W2008208071C2779450455 @default.
• W2008208071 hasConceptScore W2008208071C2779723990 @default.
• W2008208071 hasConceptScore W2008208071C2910835652 @default.
• W2008208071 hasConceptScore W2008208071C2910882873 @default.
• W2008208071 hasConceptScore W2008208071C42219234 @default.
• W2008208071 hasConceptScore W2008208071C54173615 @default.
• W2008208071 hasConceptScore W2008208071C71924100 @default.
• W2008208071 hasConceptScore W2008208071C89560881 @default.
• W2008208071 hasIssue "2" @default.
• W2008208071 hasLocation W20082080711 @default.
• W2008208071 hasLocation W20082080712 @default.
• W2008208071 hasOpenAccess W2008208071 @default.
• W2008208071 hasPrimaryLocation W20082080711 @default.
• W2008208071 hasRelatedWork W1969328028 @default.

• next